Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
19 January 2024, Israel: Biomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN,
Read More